Lilly and Incyte’s oral JAK1 and JAK2 inhibitor, Baricitinib, showed positive results in Phase IIb study
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
















